Cargando…
Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease
Plasma levels of tau phosphorylated at threonine-217 (p-tau217) is a candidate tool to monitor Alzheimer’s disease. We studied 150 cognitively unimpaired participants and 100 patients with mild cognitive impairment in the Swedish BioFINDER study. P-tau217 was measured repeatedly for up to 6 years (m...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719022/ https://www.ncbi.nlm.nih.gov/pubmed/33068398 http://dx.doi.org/10.1093/brain/awaa286 |
_version_ | 1783619607810015232 |
---|---|
author | Mattsson-Carlgren, Niklas Janelidze, Shorena Palmqvist, Sebastian Cullen, Nicholas Svenningsson, Anna L Strandberg, Olof Mengel, David Walsh, Dominic M Stomrud, Erik Dage, Jeffrey L Hansson, Oskar |
author_facet | Mattsson-Carlgren, Niklas Janelidze, Shorena Palmqvist, Sebastian Cullen, Nicholas Svenningsson, Anna L Strandberg, Olof Mengel, David Walsh, Dominic M Stomrud, Erik Dage, Jeffrey L Hansson, Oskar |
author_sort | Mattsson-Carlgren, Niklas |
collection | PubMed |
description | Plasma levels of tau phosphorylated at threonine-217 (p-tau217) is a candidate tool to monitor Alzheimer’s disease. We studied 150 cognitively unimpaired participants and 100 patients with mild cognitive impairment in the Swedish BioFINDER study. P-tau217 was measured repeatedly for up to 6 years (median three samples per person, median time from first to last sample, 4.3 years). Preclinical (amyloid-β-positive cognitively unimpaired, n = 62) and prodromal (amyloid-β-positive mild cognitive impairment, n = 49) Alzheimer’s disease had accelerated p-tau217 compared to amyloid-β-negative cognitively unimpaired (β = 0.56, P < 0.001, using linear mixed effects models) and amyloid-β-negative mild cognitive impairment patients (β = 0.67, P < 0.001), respectively. Mild cognitive impairment patients who later converted to Alzheimer’s disease dementia (n = 40) had accelerated p-tau217 compared to other mild cognitive impairment patients (β = 0.79, P < 0.001). P-tau217 did not change in amyloid-β-negative participants, or in patients with mild cognitive impairment who did not convert to Alzheimer’s disease dementia. For 80% power, 109 participants per arm were required to observe a slope reduction in amyloid-β-positive cognitively unimpaired (71 participants per arm in amyloid-β-positive mild cognitive impairment). Longitudinal increases in p-tau217 correlated with longitudinal worsening of cognition and brain atrophy. In summary, plasma p-tau217 increases during early Alzheimer’s disease and can be used to monitor disease progression. |
format | Online Article Text |
id | pubmed-7719022 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-77190222020-12-09 Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease Mattsson-Carlgren, Niklas Janelidze, Shorena Palmqvist, Sebastian Cullen, Nicholas Svenningsson, Anna L Strandberg, Olof Mengel, David Walsh, Dominic M Stomrud, Erik Dage, Jeffrey L Hansson, Oskar Brain Reports Plasma levels of tau phosphorylated at threonine-217 (p-tau217) is a candidate tool to monitor Alzheimer’s disease. We studied 150 cognitively unimpaired participants and 100 patients with mild cognitive impairment in the Swedish BioFINDER study. P-tau217 was measured repeatedly for up to 6 years (median three samples per person, median time from first to last sample, 4.3 years). Preclinical (amyloid-β-positive cognitively unimpaired, n = 62) and prodromal (amyloid-β-positive mild cognitive impairment, n = 49) Alzheimer’s disease had accelerated p-tau217 compared to amyloid-β-negative cognitively unimpaired (β = 0.56, P < 0.001, using linear mixed effects models) and amyloid-β-negative mild cognitive impairment patients (β = 0.67, P < 0.001), respectively. Mild cognitive impairment patients who later converted to Alzheimer’s disease dementia (n = 40) had accelerated p-tau217 compared to other mild cognitive impairment patients (β = 0.79, P < 0.001). P-tau217 did not change in amyloid-β-negative participants, or in patients with mild cognitive impairment who did not convert to Alzheimer’s disease dementia. For 80% power, 109 participants per arm were required to observe a slope reduction in amyloid-β-positive cognitively unimpaired (71 participants per arm in amyloid-β-positive mild cognitive impairment). Longitudinal increases in p-tau217 correlated with longitudinal worsening of cognition and brain atrophy. In summary, plasma p-tau217 increases during early Alzheimer’s disease and can be used to monitor disease progression. Oxford University Press 2020-10-17 /pmc/articles/PMC7719022/ /pubmed/33068398 http://dx.doi.org/10.1093/brain/awaa286 Text en © The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Reports Mattsson-Carlgren, Niklas Janelidze, Shorena Palmqvist, Sebastian Cullen, Nicholas Svenningsson, Anna L Strandberg, Olof Mengel, David Walsh, Dominic M Stomrud, Erik Dage, Jeffrey L Hansson, Oskar Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease |
title | Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease |
title_full | Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease |
title_fullStr | Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease |
title_full_unstemmed | Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease |
title_short | Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease |
title_sort | longitudinal plasma p-tau217 is increased in early stages of alzheimer’s disease |
topic | Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719022/ https://www.ncbi.nlm.nih.gov/pubmed/33068398 http://dx.doi.org/10.1093/brain/awaa286 |
work_keys_str_mv | AT mattssoncarlgrenniklas longitudinalplasmaptau217isincreasedinearlystagesofalzheimersdisease AT janelidzeshorena longitudinalplasmaptau217isincreasedinearlystagesofalzheimersdisease AT palmqvistsebastian longitudinalplasmaptau217isincreasedinearlystagesofalzheimersdisease AT cullennicholas longitudinalplasmaptau217isincreasedinearlystagesofalzheimersdisease AT svenningssonannal longitudinalplasmaptau217isincreasedinearlystagesofalzheimersdisease AT strandbergolof longitudinalplasmaptau217isincreasedinearlystagesofalzheimersdisease AT mengeldavid longitudinalplasmaptau217isincreasedinearlystagesofalzheimersdisease AT walshdominicm longitudinalplasmaptau217isincreasedinearlystagesofalzheimersdisease AT stomruderik longitudinalplasmaptau217isincreasedinearlystagesofalzheimersdisease AT dagejeffreyl longitudinalplasmaptau217isincreasedinearlystagesofalzheimersdisease AT hanssonoskar longitudinalplasmaptau217isincreasedinearlystagesofalzheimersdisease |